TELA Bio (TELA)
(Delayed Data from NSDQ)
$5.17 USD
+0.20 (4.02%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $5.19 +0.02 (0.39%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum F VGM
Income Statements
Fiscal Year end for TELA Bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 58 | 41 | 29 | 18 | 15 |
Cost Of Goods | 18 | 14 | 10 | 7 | 6 |
Gross Profit | 40 | 28 | 19 | 12 | 10 |
Selling & Adminstrative & Depr. & Amort Expenses | 85 | 67 | 49 | 37 | 29 |
Income After Depreciation & Amortization | -44 | -39 | -29 | -25 | -19 |
Non-Operating Income | 3 | -1 | 0 | 0 | 0 |
Interest Expense | 5 | 4 | 4 | 4 | 4 |
Pretax Income | -47 | -44 | -33 | -29 | -22 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -47 | -44 | -33 | -29 | -22 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -47 | -44 | -33 | -29 | -22 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -38 | -29 | -25 | -19 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -44 | -39 | -29 | -25 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 22.87 | 16.27 | 14.47 | 12.93 | 1.77 |
Diluted EPS Before Non-Recurring Items | -2.04 | -2.64 | -2.30 | -2.23 | -17.10 |
Diluted Net EPS (GAAP) | -2.04 | -2.72 | -2.30 | -2.23 | -17.10 |
Fiscal Year end for TELA Bio, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 17.00 | 15.05 | 14.49 | 11.91 |
Cost Of Goods | NA | 5.28 | 4.57 | 4.20 | 3.92 |
Gross Profit | NA | 11.72 | 10.48 | 10.30 | 7.99 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 24.01 | 20.67 | 20.66 | 19.25 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -12.29 | -10.19 | -10.36 | -11.26 |
Non-Operating Income | NA | 0.73 | 0.56 | 0.87 | 0.47 |
Interest Expense | NA | 1.35 | 1.33 | 1.30 | 1.25 |
Pretax Income | NA | -12.89 | -10.96 | -10.79 | -12.03 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -12.89 | -10.96 | -10.79 | -12.03 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -12.89 | -10.96 | -10.79 | -12.03 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 24.49 | 24.48 | 23.24 | 19.19 |
Diluted EPS Before Non-Recurring Items | NA | -0.53 | -0.45 | -0.46 | -0.63 |
Diluted Net EPS (GAAP) | NA | -0.50 | -0.45 | -0.46 | -0.63 |